Charles Fisher Strong Quotations

Our phase I program has indicated that oral RSD1235 can be administered safely at clinically relevant dose levels. We have seen in our intravenous (IV) trials that RSD1235 appears to be effective in converting atrial arrhythmia. Since repeat-dose safety is the major barrier to chronic use of anti-arrhythmic drugs, the strong performance of RSD1235 in these safety studies is very encouraging.

Our Phase 1 program has indicated that oral RSD1235 can be administered safely at clinically relevant dose levels. ... We have seen in our intravenous (IV) trials that RSD1235 appears to be effective in converting atrial arrhythmia. Since repeat-dose safety is the major barrier to chronic use of anti-arrhythmic drugs, the strong performance of RSD1235 in these safety studies is very encouraging.